(Q45141115)

10 December 2017

Type 1 diabetes immunotherapy: is the glass half empty or half full? (English)

1 reference

10 December 2017

0 references

1 reference

1

Kevan C Herold

1 reference

10 December 2017

Jeffrey A Bluestone

2

1 reference

PubMed ID

21832236

10 December 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

Science Translational Medicine

10 December 2017

1 reference

10 December 2017

3

1 reference

10 December 2017

95

1 reference

10 December 2017

95fs1

1 reference

Genetics, pathogenesis and clinical interventions in type 1 diabetes

10 December 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

Type 1 diabetes as a relapsing-remitting disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002981

10.1126/SCITRANSLMED.3002981

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference

PubMed ID

21832236